Objective Endothelial dysfunction occurs early in the atherosclerotic disease process, often preceding clinical symptoms. Use of menopausal hormone treatment (MHT) to reduce cardiovascular risk is controversial. This study evaluated effects of 4 years of MHT on endothelial function in healthy, recently menopausal women.
INTRODUCTION
Sex-specifi c differences in the pathophysiology, presentation, treatment and clinical outcomes of cardiovascular disease (CVD) are in the early phase of discovery [1] [2] [3] . Moreover, common CVD risk predictors may underestimate lifetime risk in both women and men 4, 5 . Identifying women ' s CVD risk early is critical for proper intervention and prevention of signifi cant adverse outcomes.
Adverse cardiovascular events correlate with loss of endothelial function [6] [7] [8] [9] . Thus, changes in endothelial function may refl ect early stages of the atherosclerotic disease process. Endothelial function is evaluated in the coronary arteries by measuring the magnitude of arterial dilatation in response to intra-coronary injection of acetylcholine during angiography 6, 8 . In the periphery, endothelial function is monitored by fl ow-induced dilatation assessed by ultrasound imaging of the brachial artery following either occlusion or arterial infusion of acetylcholine or by digital arterial tonometry recorded as a reactive hyperemia index (RHI) following occlusion of the brachial artery 10 . Flow-induced vasodilatation is affected by risk factors for CVD in asymptomatic individuals 9 and is reduced in the presence of symptomatic disease. The reduction correlates with the severity of coronary artery disease 11, 12 . Likewise, low RHI values correlate with the classic CVD risk factors of increased body mass index (BMI) and low serum high density lipoprotein (HDL) in both men and women with symptomatic coronary artery disease 7, 8 but correlation of RHI quent to the WHI reports; MHT is a Class 3 indication (i.e. contraindicated/not recommended) for primary or secondary prevention of cardiovascular disease 29 , while the North American Menopause Society, as well as the Global Consensus Statement on Menopausal Hormone Therapy, recommends MHT for women early in menopause with symptoms 28, 30 . These results have the potential to provide needed and clinically relevant information regarding the use of MHT in postmenopausal women.
METHODS

Participants
All women meeting inclusion criteria and randomized to treatment in the Kronos Early Estrogen Prevention Study (KEEPS/ NCT00154180) at Mayo Clinic, Rochester, MN, USA, were invited to participate in this ancillary study.
Women were between the ages of 42 and 59 years and were between 6 months and 3 years from their last menses at the time of enrollment. Participants had a negative history of CVD or related symptoms, were non-diabetic, and without signifi cant hyperlipidemia requiring lipid-lowering therapy. Study participants underwent testing to confi rm low CVD risk. Blood chemistries for fasting blood glucose, HDL cholesterol, low density lipoprotein (LDL) cholesterol and triglycerides were within normative ranges. None of the women smoked more than ten cigarettes a day or had untreated hypertension; BMI was Ͻ 35 kg/m 2 ; and CAC scores were Ͻ 50 Agatston units. Participants completed questionnaires reporting smoking history (never, past or current) and menopausal symptoms over the last 3 months (insomnia, hot fl ushes, night sweats and palpitations), ranking them on a numerical scale as none to mild (0 -2), or moderate to severe (3 -5). This ancillary study was approved by the Institutional Review Board at Mayo Clinic and all participants gave written informed consent for this ancillary study.
Participants were randomized to oral CEE (0.45 mg/day, oCEE), transdermal 17 β -estradiol (50 μ g/day with patches changed weekly, tE2), each with intermittent progesterone (200 mg/day for the fi rst 12 days of the month), or placebo pills and patch. Details regarding the collection of blood chemistries, carotid ultrasound and coronary calcifi cation have been reported previously 22, 31, 32 . Hormone levels were measured by high-sensitivity liquid chromatography/mass spectroscopy at the clinical core laboratory at Mayo Clinic.
Digital tonometry
A commercially available peripheral tonometer was utilized to detect changes in digital pulse volume during reactive hyperemia (EndoPAT, model 2000; Itamar Medical, Ltd., Caesarea, Israel) 8 . Participants were fasting, and had avoided caffeine and tobacco for at least 2 h prior to the test. Tests were conducted between 07.00 and 12.00.
with cardiovascular risk factors in asymptomatic individuals in the general population is equivocal 7, 13 .
Menopause represents a period of increasing risk for CVD and declining endothelial function in women 14 . Multiple observational studies have demonstrated that menopausal hormone treatment (MHT) is associated with reduced incidence and allcause CVD mortality in menopausal women [15] [16] [17] [18] [19] [20] . However, in the Women ' s Health Initiative (WHI), the risk of adverse cardiovascular events increased in women randomized to MHT consisting of conjugated equine estrogen (CEE) in combination with medroxyprogesterone acetate 21 . Endothelial function was not assessed in the WHI. It is important to note that women in the WHI were more than a decade past menopause (average age 63 years old) and not representative of women using MHT for menopausal symptoms, in contrast to the earlier reported observational studies, which showed a benefi cial effect of MHT on cardiovascular endpoints 22 . Indeed, results from basic science studies support the hypothesis that the timing of MHT initiation impacts the development of CVD such that initiation of MHT shortly after menopause reduces coronary artery atherosclerosis, whereas delayed initiation of MHT does not 23, 24 . Thus, the timing of initiation of MHT may contribute to its biological consequences 25, 26 . In a study of the long-term (10-year follow-up) effects of MHT, the risk of cardiovascular events, including death, myocardial infarction and heart failure was reduced in recently menopausal women randomized to MHT compared to placebo (hazard ratio 0.48, 95% confi dence interval 0.26 -0.87; p ϭ 0.015) with no increased risk of venous thromboembolism, cancer or stroke 27 . However, MHT is not currently recommended for prevention of CVD. Even for the approved MHT indication of treatment for severe vasomotor symptoms, no specifi c guidelines regarding formulations and routes of delivery exist. The North American Menopause Society has provided recommendations for a general approach advising ' use of the lowest dose of MHT for the shortest period of time ' when necessary for symptom relief 28 . Currently, no information exists on the effects of sustained use of lower doses of MHT delivered by oral or transdermal routes on endothelial function when initiated in recently menopausal women.
This study was designed to assess the effects of two types of MHT (oral and transdermal) compared to placebo on RHI in healthy, recently menopausal women at low risk for cardiovascular disease enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). Digital tonometry to provide the RHI was selected to provide a surrogate for endothelial function because the test is used clinically and, although less sensitive than measuring brachial arterial vasodilatation to acetylcholine, it is a non-invasive technique and thus more appealing for retaining participants in a 4-year study. We hypothesized that MHT administered to women early in menopause would have a positive effect on RHI, consistent with sustained or improved endothelial function. We also evaluated the RHI results within the context of conventional CVD risk factors, and the surrogate imaging endpoints of the main KEEPS trial, carotid intima-medial thickness (CIMT) and coronary artery calcifi cation (CAC). Much controversy has ensued subse- 
RESULTS
Baseline assessment
At baseline, 95 women participating in the KEEPS trial at the Mayo Clinic underwent RHI measurement and, of these, 83 participants had at least one follow-up measurement. As per KEEPS inclusion criteria, CVD risk factors placed these women in a low-risk category (Framingham risk score [10-year risk, %]: median ϭ 10 [1%], range ϭ 5 -15 [ Ͻ 1 -3%]) for development of a heart attack or coronary disease (Tables 1  and 2 ). At baseline, RHI averaged 2.39 ( ϩ Ϫ 0.69, n ϭ 83) and did not differ among treatment assignments ( p ϭ 0.63; Table 2 ). At baseline, the percentage of women with RHI values Ͼ 2.0 (high), 1.7 -2.0 (intermediate) or Ͻ 1.7 (low) were 69%, 16% and 15%, respectively.
Longitudinal assessment
Hormone levels
Serum levels of estrone and 17 β -estradiol measured at the last follow-up visit were signifi cantly higher in participants on treatment than placebo ( p Ͻ 0.001 for each) and, among those on treatment, estrone was higher in the oCEE group while 17 β -estradiol was higher in the tE2 group (Table 2) . Levels of sex hormone binding globulin were higher only in the oCEE group ( p Ͻ 0.001) compared to placebo, while testosterone levels did not vary signifi cantly by group ( p ϭ 0.65).
Testing was performed in a quiet room with participants in the supine position and covered with a light blanket. A blood pressure cuff was placed on the non-dominant upper arm while detection probes were placed on the index fi nger of each hand. Readings in both fi ngers were obtained for 10 min. The blood pressure cuff in the non-dominant arm was then infl ated to 200 mmHg to occlude fl ow for 5 min, after which the pressure cuff was defl ated and recordings continued for an additional 10 min. Only tests which were indicative of good arterial occlusion and test quality were used for analyses.
The RHI was calculated by dedicated software in the system computer as the average amplitude of the peripheral arterial tonometric signal over a 1-min interval beginning within 90 s after cuff defl ation divided by the mean amplitude of the 1 -3.5-min period before cuff defl ation and then normalized to those values of the dominant arm 8 . RHI was determined prior to MHT randomization (baseline) and annually thereafter for 4 years.
Statistical analysis
Linear regression was used to test for time trends in RHI levels both within and across treatment groups, with repeated measures data accounted for via the generalized estimating equations (GEE) method, assuming an exchangeable working correlation structure. This allowed the inclusion of all participants with at least one RHI measure over follow-up for optimal statistical power. Linear regression with the GEE method was also used to test for treatment effects among the repeated measures of CVD-related serum parameters (for this highsensitivity C-reactive protein (hs-CRP) and triglycerides were log-transformed) and menopausal symptom scores. Withinsubject variability of serial RHI was estimated for each participant based on the square root of residual mean squared error as derived from individual linear regression models (a model regressing RHI on time fi t separately to the data of each participant) and based on an intra-subject coeffi cient of variation (CV), which were then compared across treatment groups using one-way analysis of variance (ANOVA). For brevity, we reported only results of treatment comparisons using a ' per protocol ' analysis, in which any follow-up data subsequent to treatment drop-out was excluded. However, these analyses were also performed based on an ' intent-to-treat ' approach, and the results did not differ appreciably.
Since the analyses described above demonstrated both high variability and no signifi cant time trends in RHI measures, each participant ' s set of longitudinal data was transformed into one follow-up value using an average, which was also subtracted from their baseline value to express an average change in RHI over follow-up. Using both the average follow-up and average change measures of RHI, Spearman ' s rank correlation analysis was performed to evaluate the association of RHI response with follow-up values and changes in traditional CVD risk factors, surrogate measures of CVD, menopausal symptom scores, and estrogen levels. Since this particular analysis was not a comparison of treatments, all 
Blood chemistries
Of the CVD risk factors assessed, changes in serum levels of triglycerides were signifi cantly higher in the oCEE compared to the tE2 group ( p Ͻ 0.001) but not compared to the placebo group ( p ϭ 0.227). Changes in hs-CRP in the oCEE group were signifi cantly greater than in both the tE2 and placebo groups over follow-up ( p ϭ 0.011 and p Ͻ 0.001, respectively; Table 2 ).
RHI measurements
There was no signifi cant change in RHI over the 4-year follow-up period within any of the treatment groups or in the full combined set of participants. The variability in longitudinal RHI measurements within participants was high in each treatment group (within-subject standard deviations and CV%, averaged: 0.41 and 18.3% in the tE2 group, 0.49 and 20.5% in the oCEE group, and 0.50 and 20.5% in the placebo group) and did not differ signifi cantly across groups ( Figure 1 , p ϭ 0.31). Percentages of women with RHI values in the high ( Ͼ 2.0), intermediate (1.7 Ͻ 2.0) and low ranges ( Ͻ 1.7) are displayed in Figure 2 across study visits and by treatment group. A total of 41 (43%) women had at least one low ( Ͻ 1.7) reading over the study period.
The time trend of these RHI categories did not differ signifi cantly across the three treatment groups, neither with time defi ned on a linear scale ( p ϭ 0.075) or as a contrast between baseline and all follow-up levels pooled together ( p ϭ 0.74). Likewise, when analyzing serially measured RHI as values instead of categories, the response over time was not significantly different across treatment groups (linear time, p ϭ 0.56; contrast of baseline vs. follow-up time, p ϭ 0.90; Table 2 and Figure 3 ).
Based on a linear GEE model testing for a signifi cant change in RHI with the three treatment groups pooled together, the standard error of the coeffi cient for time, defi ned as a contrast of all follow-up measures versus baseline value, was 0.0682. In terms of a longitudinal effect, this implies that a change in RHI of 2.8 ϫ 0.0682 ϭ 0.19 units (i.e. a 0.19 unit shift between baseline and pooled follow-up values) is detectable with 80% power. Alternatively, using a more effi cient analysis that assumes the change in RHI over time follows a linear trend, a separate model was fi tted with a linear effect for time (years from baseline visit). Based on a standard error of 0.0184, the detectable difference is 2.8 ϫ 0.0184 ϫ 1 ϭ 0.10 
Menopausal symptom scores
Changes in the aggregate menopausal symptom scores were different among groups ( p ϭ 0.004). Reductions in self-reported severity of hot fl ushes ( p Ͻ 0.001) and night sweats ( p ϭ 0.002) were signifi cantly greater in the two treatment groups compared to the placebo group (Figure 4) .
RHI measurement correlations
Consistent with the fi nding of no signifi cant change in RHI over time, changes in RHI (averaged over follow-up) did not signifi cantly correlate with changes in CVD risk factors nor with end-of-study estrogen levels (Table 3) . However, there was a nominally signifi cant inverse correlation between the change in RHI values and the change in CIMT relative to baseline (Spearman correlation coeffi cient ρ ϭ -0.268, p ϭ 0.012; Figure 5 ). There was no correlation with change in RHI values with changes in CAC scores. However, the change in average severity of night sweats (relative to baseline) had a nominally signifi cant inverse correlation with change in average RHI (Spearman ρ ϭ -0.252, p ϭ 0.016; Figure 6 ).
DISCUSSION
These observations are the fi rst to provide longitudinal assessment of endothelial function using the non-invasive digital tonometry technique in recently menopausal women with a low-risk cardiovascular profi le and the impact of MHT on those measurements. There are several important conclusions from this study. First, using this technique and contrary to the hypothesis, it was not possible to detect an effect of MHT on endothelial function by RHI. This neutral outcome could refl ect two possibilities: (1) effi cacy of treatment or (2) the sensitivity of the measurement. First, functional effi cacy of treatment is confi rmed by increases in Figure 3 Change in reactive hyperemia index (RHI) values from baseline in each treatment group over the course of the study. In order to reduce the effect of variability, an average RHI value was calculated for each woman for those years for which there were follow-up measurements and those were averaged for each year. Data are shown as the mean ϩ Ϫ standard deviation for the change within each time point by treatment group serum levels of both estrone and 17 β -estradiol in the MHT groups, maintenance of bone density 33 and relief of menopausal symptoms, especially vasomotor symptoms (hot fl ushes) and night sweats (Figure 4) . However, the threshold for treatment effects on some endothelial functions may not have been reached. Serum levels of 17 β -estradiol in participants of the present study averaged 36 pg/ml, whereas, in studies measuring endothelial function by reactive hyperemia by ultrasound 34 and changes in serum levels of nitric oxide 35 , serum 17 β -estradiol averaged 144 pg/ml and 76 pg/ml, respectively. Although serum levels of hormone may not refl ect the concentrations at the tissue level where conversion of estrone to 17 β -estradiol may occur, the possibility remains that the doses of hormone used in KEEPS were below the threshold to sustain some endothelial function postmenopause. Another possibility is that progesterone may counter effects of estrogen on endothelial function 36 , but this seems unlikely as only measurements at 36 months were made during the active progesterone treatment and these values were not different from those obtained during the estrogen-only phase of treatment 37 .
The second possibility is that the study may have been biased against observing effects of MHT on endothelial function due to the variability in the RHI method. Variability in RHI was unexpectedly high and serves as a caution in the utility of digital tonometry to detect subtle changes in risk factor profi le or treatment effects as would be needed to add value to existing cardiovascular risk algorithms. Changes in blood fl ow to the fi nger as a measure of arterial endothelial function may be less sensitive than measurement of changes of brachial artery diameter by ultrasound due to arterial -venous anastomoses in the fi nger and the infl uence of adrenergic neurotransmission on vasomotor tone in the digits 10 . Indeed, the inverse association between changes in reported night sweats and changes in RHI scores suggests that measurement of reactive hyperemia by digital tonometry may refl ect, to some extent, contributions of the autonomic nervous system 10 , which may also account for the variability among groups. In addition, accumulation of metabolites may follow the 5 minutes of occlusion of the brachial artery as needed for the operation of the machine. These metabolites will also modulate local vasomotor tone that would alter the response to changes in shear stress of Although two studies comparing reactive hyperemia by brachial artery ultrasound to digital arterial tonometry found a correlation between the two measurements 39, 40 , both studies were biased toward males with coronary artery disease and included participants using medication for heart disease. Thus, a single measure of RHI may provide value in identifying symptomatic, non-occlusive coronary disease but not for discerning early disease processes.
However, longitudinal changes in RHI may refl ect some functional alterations within the vascular wall as decreases in RHI, independent of treatment, correlated with increases in CIMT (Figure 5) , suggesting a functional relationship between endothelial (vascular) responsiveness to occlusive hyperemia and vascular remodeling. While the magnitude of this correlation was fairly weak and the level of signifi cance unadjusted for multiple testing, an ad hoc analysis revealed a signifi cant reduction in RHI within a portion of these women deemed to have appreciable objective atherosclerotic change. In particular, choosing a margin of Ͼ Ϫ 0.05 mm as signifying a ' real ' increase in CIMT based on the range of negative changes in Figure 2 (a crude approximation of the measurement error since this measure should not decrease over time), this of local metabolites which accumulate during the cuff occlusion. Alternatively, it may refl ect the inherent variability of the test itself. RHI variability may partially be explained by differences in brachial artery diameter as a negative association has been described between brachial artery diameter and RHI. Accounting for brachial artery diameter eliminated gender differences in RHI measurements 41 . Additionally, the study was not powered to demonstrate hormonal effects on endothelial function by this test based on the observed variability which was similar among groups.
CONCLUSION
This study is the fi rst to provide longitudinal data on digital tonometry and its variability among recently menopausal women who are healthy and asymptomatic of cardiovascular disease and who are using two different formulations and delivery modalities of MHT. These MHT regimes and dosages are relevant to current clinical practice and did not adversely affect endothelial function, as measured by digital tonometry, in healthy, recently menopausal women. These observations
